SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences informs about press release

28 May 2025 Evaluate
Zydus Lifesciences has informed that it enclosed a copy of press release dated May 28, 2025, titled ‘Zydus receives USFDA ‘Fast Track Designation’ for Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of Amyotrophic Lateral Sclerosis (ALS)’. The contents of the press release give full details. 

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

930.85 7.75 (0.84%)
15-Apr-2026 10:10 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1214.10
Cipla 1223.90
Zydus Lifesciences 930.85
Lupin 2334.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×